2nd Annual Inhaled Drug Delivery Virtual Summit 2021
Conference Overview
The recent years have witnessed major growth in the inhaled drugs market driven by rising prevalence of chronic pulmonary diseases, the evolution of inhaled therapies and technological advancements in device development. Challenges still remain to ensure safe and efficient respiratory drug delivery - including device and drug integration, particle engineering and formulation technologies, clinical studies and regulatory pathways. Our meeting facilitates hands-on experience sharing of successful development of inhaled drug products for enhanced patient care.
The featured talks on:
- Understanding of regulations and requirements for OINDPs
- Aerodynamics and Air Flow Resistance of DPIs
- Using the inhalation route to delivery drugs to the systemic circulation
- Lung on chip applications in respiratory health
- Translating Inhaled and Nasal Technologies for the Delivery of Biologics
- Inhalation of therapeutics to fight respiratory tract infections
- Transnasal Pulmonary Drug Delivery in Acute and Critical Care – Practice to Promise
- The climate is changing for metered dose inhalers
- Practical challenges with developing inhalation drugs during pre-clinical testing
- From perception to use - the patient DPI product interface
- Are sustainability, reusability and carbon neutrality major trends for devices in the future? A case study of Respimat® re-usable
- The impact of filling technology selection for dry powder formulations on device performance, process consistency and commercial scale-up
- Postmarket Safety reporting for Combination products in the US
- ICOpre - Development of a generic DPI platform for a global market
Who You Will Meet
By Seniority Level
- C-Level, Presidents, Chairs, Members of the Board & VPs
- Vice presidents, Directors, & Heads
- Leaders & Managers
- Principals, Engineers, Analysts & Scientists
- Instructors & Trainers & Teachers
- Advisors, Coordinators, Auditors & Consultants
- Other Professionals, Experts & Specialists
By Divisions
- Aerosols
- Asthma
- Combination Products
- Connective Health
- COPD
- Cystic Fibrosis
- Device Development & Engineering
- Drug Development & Delivery
- Dry Powder Inhalers
- E-Health
- Formulation Development
- Generics
- Inhalation Delivery
- Inhalation Product Development
- Inhalation Products
- Inhaled Dosage Forms
- Medical Devices
- Metered Dose Inhalers
- Nasal Delivery
- New Materials
- Particle Characterisation
- Process Development
- Pulmonary Delivery
- Pulmonary Diseases
- R&D
- Regulatory Affairs
- Respiratory Delivery
- Respiratory Drug Delivery & Development
- Respiratory Supply Chain
- Respiratory Therapeutics
- Respiratory Pharmacology
- Scientific Research
- Marketing & Business Development
By Industries
- Pharmaceutical
- Biotechnology
- Medical Devices
- Plastics
- Chemicals
- CMO/ CDMO
- CRO
- NOP
- Other
By Region
- Central and Eastern Europe
- North America
- Middle East and Africa
- Asia-Pacific
- Other
Conference Programme
Day One - Thursday 05, August 2021
Tentative Schedule:
Central European Summer Time (CEST, Prague, UTC/GMT +2 hours)
12:00 Registration
12:20 Opening Address
12:30 Understanding of regulations and requirements for OINDPs.
- Overview of E&L for OINDPs
- What are Extractables and leachables
- Why most important for OINDPs
- Brief over view of regulations
- Case studies
Andrew Feilden,
Director Analytical Sciences, Bicycle Therapeutics, Shawbury, United Kingdom
13:00 Questions & Answers
13:10 Aerodynamics and Air Flow Resistance of DPIs
- Introduction – The relevance of the air flow resistance
- The air flow inside of a DPI – An engineer’s perspective
- Interaction with formulation – A completely different story
- Basic approach using a bypass – visualisation and modelling
- Summary
Herbert Watchel,
Senior Principal Scientist, Boehringer Ingelheim Pharma GmbH & Co. KG, DE, Germany
13:40 Questions & Answers
13:50 Break
14:00 Using the inhalation route to delivery drugs to the systemic circulation.
- Advantages and limitation of the pulmonary route to the systemic circulation
- Requirements for distal lung aerosol delivery
- Medicines for systemic inhalation therapy on the market and in the development pipeline
- Critical assessment of factors governing the success (or failure) of systemically inhaled products
Dr. Carsten Ehrhardt,
Professor in Pharmaceutics and Biopharmaceutics, Trinity College Dublin, Ireland
14:30 Questions & Answers
14:40 Lung on chip applications in respiratory health
Nina Hobi,
CEO & Scientific Director, AlveoliX AG, Bern, Switzerland
15:10 Questions & Answers
15:20 Translating Inhaled and Nasal Technologies for the Delivery of Biologics.
- Overview of currently available technologies and successfully marketed products.
- Review of the development challenges that might be encountered — and the solutions that are available — when formulating these delivery routes.
- A focus on analytical approaches for impurity identification and quantification.
- Key considerations when rapidly repurposing existing products for inhaled delivery.
Inhaled and nasal delivery platforms have specific applications outside of their traditional uses for asthma/chronic obstructive pulmonary disease (COPD) and seasonal rhinitis/sinusitis: They can offer real advantages for the delivery of therapeutic biologics.
Mark Parry,
Technical Director, Intertek Pharmaceutical Services, United Kingdom
16:05 Questions & Answers
16:15 Break
16:25 Inhalation of therapeutics to fight respiratory tract infections
- Inhalation addresses drugs topically as an aerosol through the nose and/or mouth to its site of action in the respiratory tract. Actually, inhalation is the gold standard for the delivery of drugs with topical action to treat asthma, chronic obstructive respiratory disease (COPD) or cystic fibrosis (CF).
- Inhalation provides a better therapeutic index for some drugs, often requires reduced dose as compared to other routes and is non-invasive, improving patient compliance and comfort.
- Presently, most (topical) inhaled drugs are small molecules from different classes. Despite the obvious theoretical advantages of topical administration for therapeutics antibody (Ab) by inhalation, few of these benefits have yet materialized in the clinics.
- This paucity highlights the complexity of developing inhaled antibodies and points out the persisting hurdles to overcome. A detailed understanding of the biology and pharmacology of inhaled Ab is required to ensure the successful transition from pre-clinical to clinical assessment.
Thomas Sécher,
Scientist, INSERM, France
16:55 Questions & Answers
17:05 Transnasal Pulmonary Drug Delivery in Acute and Critical Care – Practice to Promise..
- Administration of medical aerosols to the lung of our sickest patients has multiple challenges in the critical care environment including the need to not interrupt oxygen and ventilatory support.
- Aerosol delivery via High Flow Nasal Oxygen is used by >70% of intensivists worldwide for a variety of applications, with expanding knowledge of best practices of optimal delivery efficiency achieving double digit delivery efficiency in both preterm infants and adults.
- Knowable and controlable, transnasal pulmonary aerosol delivery has the promise of efficient and consistent administration of a wide range of formulations supporting development and approval of inhaled medications for management of the critically ill.
James B Fink, PhD, RRT, FAARC, FCCP,
Chief Scientific Officer, Aerogen Pharma Corp., San Mateo, CA, USA
17:35 Questions & Answers
17:45 Closing remarks and end of day one
Day Two - Friday 06, August 2021
Tentative Schedule:
Central European Summer Time (CEST, Prague, UTC/GMT +2 hours)
12:00 Registration
12:20 Opening Address
12:30 The climate is changing for metered dose inhalers.
- Increases in global temperature are already having a significant impact on our climate. The hydrofluorocarbon (HFC) propellants used today in pressurized metered-dose inhalers (pMDIs) have global warming potential (GWP) many times that of carbon dioxide. This has prompted calls to switch patients to dry powder inhalers (DPIs)
- Dry powder inhalers are often more expensive than the equivalent pMDI. A wholesale switch of reliever medications would lead to significant increases in the cost of these life-saving medications
- At the same time, it is projected that there may be a 5-fold increase in the cost of pharmaceutical grade propellants in the next few years. This may lead to a price increase in reliever medication
- At least two companies are now working to develop pMDIs using propellants which are potentially cheaper in the long-term and have much lower GWP
Dr. John N Pritchard
Independent Business Owner, Inspiring Strategies, Leicester, United Kingdom
13:00 Questions & Answers
13:10 Practical challenges with developing inhalation drugs during pre-clinical testing.
- Extrapolating from clinical to pre-clinical and regulatory expectations
- Study designs – what is different for inhalation studies – histo, animal numbers or not, dose calculation
- NCEs vs biologics – differences or not
- Aerosol generation, exposure systems, aerosol sampling, additional DFA/FIA support
- Animal welfare considerations – TK blood volumes, BAL collection, limitations of dosing wrt time, dosing large animals – animal compliance
Dr. Simon Moore, BSc(Hons) PhD MRSC,
Global Lead of Inhalation Sciences and Engineering, Covance Laboratories, United Kingdom
13:40 Questions & Answers
13:50 Break
14:00 From perception to use - the patient DPI product interface.
- Patient characteristics and therapeutic complexity
- DPI product administration from a patient perspective
- The role of learning, intuition and standardization
- TDPI product design to improve therapeutic outcomes
Sven Stegemann,
Professor for Patient Centric Drug Development and Manufacturing, Graz University of Technology, Graz, Austria
14:30 Questions & Answers
14:40 Are sustainability, reusability and carbon neutrality major trends for devices in the future? A case study of Respimat® re-usable.
- Historic and upcoming political initiatives
- Carbon footprint and neutrality
- Respimat® re-usable - technology and performance
- Sustainability goes beyond design
Dr. Felix Weiland,
Head of Product & Process Technology, Boehringer Ingelheim microParts GmbH, Gütersloh, Germany
15:10 Questions & Answers
15:20 Break
15:30 The impact of filling technology selection for dry powder formulations on device performance, process consistency and commercial scale-up
- Consistent high efficiency aerosoliation performance is a critical quality attribute for all dry powder inhalers. There is a strong dependant relationship between the powder formulation, filling technology, device design and the device performance.
- The desire to deliver a wider range of molecular types of drug has promoted a large increase in the use of engineered particle technologies e.g. spray drying for DPIs which require careful consideration of process conditions.
- Highlight the impact of filling technology on device performance, process efficiency and manufacturing throughput. Could selection of the right filling technologies enable increased formulation and device design spaces.
- Assess the potential issues due to filling technology with process scale-up to achieve continuity of performance as you move from bench, through clinic to commercial; minimising risk in the development process.
- Affirm the importance of early stage filling trials on formulation selection and device design.
Tom French,
Device Industrialisation Engineer, 3P innovation, United Kingdom
15:10 Questions & Answers
16:20 Postmarket Safety reporting for Combination products in the US
- What are the regulatory requirements
- Discussion of key challenges
- Walk through a reportable event case scenario
Khaudeja Bano, MD,
Executive Medical Director, Combination Product Safety Head Global Patient Safety & Pediatrics, Amgen, USA
16:50 Questions & Answers
17:00 ICOpre - Development of a generic DPI platform for a global market
Generic versions of marketed dry powder inhaler (DPI) drug products represent an attractive market opportunity. In the coming years, GSK’s Ellipta platform is the largest opportunity with several drug substance patents expiring. However, development of generic DPI drug products is a complicated process with many challenges. Complex drug-device interactions represent a major hurdle to achieve therapeutic equivalence. The very intricate patent landscape in combination with the requirement of similar user-handling and flow resistance limits the design options. The need for cost-efficient development and low manufacturing costs adds additional complexity. There is a great need to replace injections with safe and low cost inhaled drug delivery. Iconovo’s unit-dose inhaler ICOone is currently used in two ongoing projects on inhaled oxytocin and inhaled covid-19 vaccine.
- Overview of market and patent situation.
- Regulatory requirements on generic inhalation products.
- Initial choice – copy original or develop new technology.
- Concurrent development of device and formulation.
- ICOone – inhalation instead of injection.
Dr. Orest Lastow,
Chief Technology Officer & Founder, Iconovo AB, Malmo, Sweden
17:30 Questions & Answers
17:40 Closing remarks and end of summit
Registration Form
To register to the summit as a Delegate, please provide the details below. Once the form is submitted, we will send you the official confirmation and the invoice for payment. In case of doubt, contact us at info@qepler.com.
*Please note, all participation packages, contains complete conference materials distribution after the event (Slides, list of participants, stream and video recording). You don't need to order an additional "Documentation Packages".
ONLINE Participation:
ONLY
RECORDING
 
Video RecordingSlide Decks
List of Participants
Authorized Presentations ONLY
Registration Form
To register to the summit as a Delegate, Exhibitor or Sponsor, please provide the details below. Once the form is submitted, we will send you the official confirmation and the invoice for payment. In case of doubt, contact us at info@qepler.com.
*Please note, all participation packages, contains complete conference materials distribution after the event (Slides, list of participants, stream and video recording). You don't need to order an additional "Documentation Packages".
Online Sponsorship:
05 August 2021
Speaker
Sponsorship Package
- 1 pass included
- Additional pass: €245
- Session: 20 minutes
- Logo and URL placement
- Social media recognition
05 August 2021
Partner
Sponsorship Package
- 2 passes included
- Additional pass: €195
- Session: 30 minutes
- Logo and URL placement
- Social media recognition
- Colour advert in agenda: 1/2 page
- Promotional materials distribution
- Link to Landing page
05 August 2021
Gold
Sponsorship Package
- 3 passes included
- Additional pass: €145
- Session: 40 minutes
- Logo and URL placement
- Social media recognition
- Colour advert in agenda: 1 page
- Promotional materials distribution
- Link to Landing page
- Link to Virtual Exhibition page
- Keynote presentation: 15 minutes
- Chairing of Day 1 or 2
Newsletter Form
Please fill in the details below to get the latest news, discounts, early-bird rates, and upcoming annual details.
Buy Document Form
€395 - Documentation Package, includes complete conference materials.
Post-event presentations with video recording, slide decks, a list of participants, and other promotional materials.
*The presentation content is subject to speaker’s companies approval for distribution.
Slide Decks
List of Participants
Authorized Presentations ONLY
Meet our Speakers
Dr. John N Pritchard
Independent Business OwnerInspiring Strategies
Sven Stegemann
Professor for Patient Centric Drug Development and ManufacturingGraz University of Technology
Khaudeja Bano
Executive Medical Director, Combination Product Safety Head Global Patient Safety & PediatricsAmgen
Our Sponsors
Intertek WEBINARS
3P innovation useful links:
- Virtual Showroom: Virtual Showroom
- White Paper: How to reduce development and clinical manufacturing timescales with robotic filling innovation
SNAPSHOT OF ATTENDEES 2021
3P innovation, UK - Abdi İbrahim Pharmaceuticals, TR - Accord Healthcare GmbH, DE - Ache Laboratories Pharmaceutics, BR - Aerogen Pharma Corp., USA - AlveoliX AG, CH - Amgen, USA - Arla Foods, UK - Aspen, ZA - Bayer AG, DE - BioCryst, USA - Biovital, DZ - Boehringer Ingelheim microParts GmbH, DE - Boehringer Ingelheim Pharma GmbH & Co. KG, DE - Broughton, UK - Cambridge Design Partnership, UK - CEA , FR - Covance Laboratories, UK - CSL Behring, CH - CSL Behring, DE - DPSRU, IN - Dr. Reddy's Laboratories, IN - E.Z. Solutions Pvt. Ltd. (InveniAI), IN - Evalueserve Pvt Ltd, IN - Explicat Pharma GmbH, DE - Franz Ziel GMBH, DE - Fresenius Kabi Oncology Ltd, IN - GlaxoSmithKline, UK - Glenmark , IN - Graz University of Technology, AT - GSK, UK - Hall Analytical, UK - Hollycon Italy PTE. LTD. Srl, IT - Hovione, PT - i2c Pharmaceutical Services, UK - Iconovo AB, SE - INSERM, FR - Insmed, USA - Inspiring Strategies, UK - Intertek (Schweiz) AG, CH - Intertek Pharmaceutical Services, UK - Iran university of medical sciences, IR - Janssen Pharmaceuticals, USA - Janssen Pharmaceuticals, BE - KIET SCHOOL OF PHARMACY, IN - Kindeva Drug Delivery , UK - Kusum Health Care Pvt. Ltd., IN - OM Pharma Suisse AG, CH - Pharmaceutical Research Center , IN - Pieris Pharmaceuticals GmbH, DE - RAUMEDIC AG, DE - Roskamp Institute, USA - RSSL, UK - Sandoz, USA - Sudair Pharmaceuticals Company, SA - Surface Measurement Systems Ltd., DE - Tavanta Therapeutics Hungary Inc, HU - Teva Branded Pharmaceuticals R&D, USA - Trinity College Dublin, IE - UCB Biopharma SRL, BE - World Health Organization, CH - Xedev, BE - Yuria-Pharm LLC, UA - Zeab Therapeutic Ltd., IN - and others.
PREVIOUS EVENT
SNAPSHOT OF ATTENDEES
3M United Kingdom PLC - 4Pharma - Agartee Technology Inc. - AGES - Medizinmarktaufsicht LCM/QUAL - Aptar Pharma - Aptuit Srl - Boehringer Ingelheim - Boehringer Ingelheim microParts GmbH - Covestro Deutschland AG - CSL Behring - CSL Behring GmbH - Emmace Consulting AB - Ferring Pharmaceuticals - GlaxoSmithKline - Graz University of Technology - Harro Höfliger Verpackungsmaschinen GmbH - Iconovo AB - Inspiring Strategies - JSC «FARMAK» - Nanologica - Novartis - Pari - Paul Johnson Consulting Limited - Saarland University - Skyepharma AG (Vectura Group) - Smithers Rapra Ltd - Softhale NV - Trinity College Dublin - Others